Piper Sandler Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS - Free Report) had its price target hoisted by Piper Sandler from $21.00 to $24.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

HIMS has been the subject of several other research reports. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Monday, December 2nd. Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 target price on the stock. Needham & Company LLC lifted their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Monday. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $24.07.

Hims & Hers Health Stock Up 0.7 %

Hims & Hers Health stock traded up $0.19 during mid-day trading on Monday, reaching $26.82. 9,029,169 shares of the company's stock were exchanged, compared to its average volume of 8,615,215. The business's fifty day simple moving average is $26.66 and its 200 day simple moving average is $21.50. Hims & Hers Health has a one year low of $8.14 and a one year high of $35.02. The firm has a market capitalization of $5.86 billion, a PE ratio of 60.96 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) EPS. On average, sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares of the company's stock, valued at $1,399,273.20. This represents a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total value of $47,738.99. Following the sale, the insider now directly owns 172,274 shares of the company's stock, valued at approximately $3,516,112.34. This trade represents a 1.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,064,514 shares of company stock worth $26,712,334. 17.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after acquiring an additional 2,152 shares during the last quarter. Quest Partners LLC boosted its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health in the second quarter worth about $111,000. Finally, Quarry LP lifted its stake in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company's stock valued at $113,000 after acquiring an additional 2,913 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.